Affordable Access

Publisher Website

Association Between ADHD and COVID-19 Infection and Clinical Outcomes: A Retrospective Cohort Study From Electronic Medical Records.

Authors
  • Heslin, Kathleen P1
  • Haruna, Aminat1
  • George, Regina A2
  • Chen, Shiyu1
  • Nobel, Ishak1
  • Anderson, Kathryn B3, 4
  • Faraone, Stephen V5, 6
  • Zhang-James, Yanli5
  • 1 Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA.
  • 2 Department of Psychology, University of Alabama, Tuscaloosa, AL, USA.
  • 3 Institute for Global Health and Translational Sciences, SUNY Upstate Medical University, Syracuse, New York.
  • 4 Department of Microbiology and Immunology, SUNY Upstate Medical University, Syracuse, New York.
  • 5 Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, New York.
  • 6 Department of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, New York.
Type
Published Article
Journal
Journal of Attention Disorders
Publisher
SAGE Publications
Publication Date
Jan 01, 2023
Volume
27
Issue
2
Pages
169–181
Identifiers
DOI: 10.1177/10870547221129305
PMID: 36264064
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Though psychiatric illnesses have been associated with increased COVID-19 infection risk, limited information exists about the relationship between ADHD and COVID-19. Using the TriNetX COVID-19 Research Network, we examined the impact of ADHD diagnosis and treatment on COVID-19 infection rates and outcomes. ADHD patients had greater risk of COVID-19 (risk ratio (RR) 1.11, 95% CI [1.09, 1.12]). Increased risk was higher in females than males, and highest among Asian and Black patients. Within 60 days after COVID-19 diagnosis, ADHD patients had lower rates of hospitalization (RR 0.91, 95% CI [0.86, 0.96]) and mechanical ventilation (RR 0.69, 95% CI [0.58, 0.83]), and a nonsignificant reduced death rate (RR 0.65, 95% CI [0.42, 1.02]). Patients who recently received ADHD medication had higher rates of COVID-19 (RR 1.13; 95% CI [1.10, 1.15]). ADHD poses increased risk for COVID-19, but may reduce risk of severe outcomes. ADHD medications modestly impacted COVID-19 risk.

Report this publication

Statistics

Seen <100 times